“We recently announced positive data from our Phase 2/3 study of tovecimig and look forward to meeting with the FDA before filing a BLA later this year. Most patients with BTC have no approved therapeutic option in the second line setting. Tovecimig, with its strong response rate, striking progression benefit and impact on overall survival would be a compelling treatment alternative for these patients,” said Thomas Schuetz, Chief Executive Officer and Vice Chairman of the Board of Directors.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Micron initiated, Rambus downgraded: Wall Street’s top analyst calls
- Compass Therapeutics price target lowered to $7 from $13 at Canaccord
- Compass Therapeutics downgraded to Market Perform from Outperform at Raymond James
- Compass Therapeutics price target lowered to $6 from $12 at Stifel
- Compass Therapeutics selloff ‘an over-reaction,’ says Jefferies